• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Almirall reorganizes in Europe, cuts 250 positions

Almirall reorganizes in Europe, cuts 250 positions

December 6, 2013
CenterWatch Staff

Pharmaceutical company Almirall has reorganized in Europe to optimize its portfolio potential. Pharmaceutical markets in Europe, particularly in Spain, have been affected in recent years by economically driven decisions made by various countries’ health authorities that have negatively affected the growth of those markets and the introduction and uptake of new products. 

Eduardo Sanchiz, CEO of Almirall, said, "We have been investing heavily over the last few years to maximize the potential of our portfolio of new products. However these efforts are happening at a time of unprecedented challenges in our industry and in key markets for our company. We have growth opportunities ahead of us and we will only manage to achieve them if we rebalance our resources and focus our efforts where we are in a better position to realize long term success." 

In Spain, as a result of key decisions taken by health authorities, the pharmaceutical market has been contracting for four consecutive years and growth is not expected in the short term. Almirall's performance, despite the introduction of new products, has followed this trend.

The reorganization will affect its structure in Spain, where it could affect 250 positions. The measures implemented up to now to contain costs, realize synergies and improve competitiveness in Spain, while effective, have not been enough to reach the desired objectives. 

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing